Chief, Division of Infectious Diseases
Denver Health Medical Center
- Hepatitis C virus (HCV) and HIV coinfection
- In vitro assessment of novel antiviral drugs
- HCV resistance
- Viral fitness
- Early clinical trials of new antiviral drugs (phase I and II)
Dr Wyles is a Chief, Division of Infectious Diseases at Denver Health Medical Center. His research interests include the in vitro evaluation of new anti-HCV compounds and clinical trials of anti-HCV compounds in HCV and HCV/HIV co-infected subjects. He serves as an attending physician on the infectious diseases and internal medicine services at the University of California San Diego teaching hospitals. He is an Instructor in the School of Medicine Medical Microbiology laboratory course.
- Member, Infectious Diseases Society of America
- Contributor, Expert Perspectives III: Strategies for the Management of HIV/HCV Co-Infection (2002)
- Advisor/Instructor, Colorado AIDS Education and Training Center: Hepatitis C Virus Center for Excellence (2002-2005)
- Consultant, Colorado AIDS Education and Training Center: Hepatitis C Virus Center for Excellence (2005-present)
- Tau Beta Pi, Engineering Honor Society
- GlaxoSmithKline HIV Fellow
- Northwestern University, BS Biomedical Engineering (1993)
- Northwestern University Feinberg School of Medicine, MD (1998)
- University of Colorado Health Sciences Center, Residency in Internal Medicine (1998-2001)
- University of Colorado Health Sciences Center, Fellowship in Infectious Diseases (2001-2004)
- Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174-181.
- Wyles DL, Gerber JG. Abacavir pharmacokinetics in hepatic dysfunction. Clin Infect Dis. 2005;40:909-910.
- Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007;81:3005-3008.
- Grünberger C, Wyles DL, Kaihara KA, Schooley RT. Three-drug synergistic interactions of small molecular inhibitors of HCV replication. J Infect Dis. 2008;197:42-45.
Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY. The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother 2009; 53(6):2660-2.
6. Parsons J, Castaldi MP, Dutta S, Dibrov SM, Wyles DL, Hermann T. Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA. Nat Chem Biol 2009; 5(11):823-5.